Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.

2002496 citationsJournal Article

Authors

Howard L. Corwin · Dartmouth–Hitchcock Medical Center

Andrew Gettinger

for the EPO Critical Care Trials Group

Abstract

In critically ill patients, weekly administration of 40 000 units of rHuEPO reduces allogeneic RBC transfusion and increases hemoglobin. Further study is needed to determine whether this reduction in RBC transfusion results in improved clinical outcomes.

Topics & Keywords

Blood transfusion and management Erythropoietin and Anemia Treatment Blood groups and transfusion

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 288, Issue 22, pp. 2827-35

DOI: 10.1001/jama.288.22.2827

Field-Weighted Citation Impact: 15.84